[go: up one dir, main page]

FR2921269B1 - UTILISATIONS DE 2-°PIPERIDINYL!METHYL-2,3-DIHYDROIMIDAZO°1,2 -c!QUINAZOLIN-5(6H)-ONE POUR FOURNIR UN EFFET ANALGESIQUE,UN EFFET ANTIALLERGIQUE ET UN EFFET D'ANTAGONISME AUX RECEPTEURS HISTAMINIQUES H1 - Google Patents

UTILISATIONS DE 2-°PIPERIDINYL!METHYL-2,3-DIHYDROIMIDAZO°1,2 -c!QUINAZOLIN-5(6H)-ONE POUR FOURNIR UN EFFET ANALGESIQUE,UN EFFET ANTIALLERGIQUE ET UN EFFET D'ANTAGONISME AUX RECEPTEURS HISTAMINIQUES H1

Info

Publication number
FR2921269B1
FR2921269B1 FR0800916A FR0800916A FR2921269B1 FR 2921269 B1 FR2921269 B1 FR 2921269B1 FR 0800916 A FR0800916 A FR 0800916A FR 0800916 A FR0800916 A FR 0800916A FR 2921269 B1 FR2921269 B1 FR 2921269B1
Authority
FR
France
Prior art keywords
effect
dihydroimidazo
quinazolin
antagonism
antiallergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0800916A
Other languages
English (en)
Other versions
FR2921269A1 (fr
Inventor
Feng Nien Ko
Yuan Ling Ku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical and Pharmaceutical Industry Technology and Development Center
Original Assignee
Medical and Pharmaceutical Industry Technology and Development Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical and Pharmaceutical Industry Technology and Development Center filed Critical Medical and Pharmaceutical Industry Technology and Development Center
Publication of FR2921269A1 publication Critical patent/FR2921269A1/fr
Application granted granted Critical
Publication of FR2921269B1 publication Critical patent/FR2921269B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention décrit de nouvelles utilisations de 2-[pipéridinyl]méthyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one pour fournir un effet analgésique chez un patient, pour traiter une anaphylaxie cutanée passive chez un patient et pour induire un effet d'antagonisme aux récepteurs histaminiques H1chez un patient pour traiter une maladie ou un trouble comme une allergie.
FR0800916A 2007-09-25 2008-02-20 UTILISATIONS DE 2-°PIPERIDINYL!METHYL-2,3-DIHYDROIMIDAZO°1,2 -c!QUINAZOLIN-5(6H)-ONE POUR FOURNIR UN EFFET ANALGESIQUE,UN EFFET ANTIALLERGIQUE ET UN EFFET D'ANTAGONISME AUX RECEPTEURS HISTAMINIQUES H1 Active FR2921269B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0718678A GB2453116B (en) 2007-09-25 2007-09-25 Uses of 2-[piperidinyl]methy1-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect

Publications (2)

Publication Number Publication Date
FR2921269A1 FR2921269A1 (fr) 2009-03-27
FR2921269B1 true FR2921269B1 (fr) 2010-05-28

Family

ID=38670457

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0800916A Active FR2921269B1 (fr) 2007-09-25 2008-02-20 UTILISATIONS DE 2-°PIPERIDINYL!METHYL-2,3-DIHYDROIMIDAZO°1,2 -c!QUINAZOLIN-5(6H)-ONE POUR FOURNIR UN EFFET ANALGESIQUE,UN EFFET ANTIALLERGIQUE ET UN EFFET D'ANTAGONISME AUX RECEPTEURS HISTAMINIQUES H1

Country Status (7)

Country Link
US (2) US20090082373A1 (fr)
JP (1) JP4845895B2 (fr)
CN (1) CN101396365B (fr)
DE (1) DE102008003054A1 (fr)
FR (1) FR2921269B1 (fr)
GB (2) GB2454549B (fr)
TW (1) TWI364280B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178523B (en) * 1979-05-18 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for preparing new pyrazolo-quinazoline derivatives
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3220438A1 (de) * 1982-05-29 1983-12-01 Troponwerke GmbH & Co KG, 5000 Köln Chinazolinonderivate, verfahren zu ihrer herstellung und ihre verwendung inn arzneimitteln
JPH0222274A (ja) * 1988-01-23 1990-01-25 Kyowa Hakko Kogyo Co Ltd ピリダジノン誘導体
US5158953A (en) 1991-08-13 1992-10-27 National Science Council 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof
US5512677A (en) 1991-08-13 1996-04-30 National Science Council 3-substituted methyl-2,3-dihydroimidazo 1,2-c!quinazoline derivatives, the preparation and use thereof
US5185953A (en) 1991-08-16 1993-02-16 Gross Allen W Rodent extermination device
JPH0768245B2 (ja) * 1991-11-01 1995-07-26 ナショナル サイエンス カウンシル ２−置換メチル−２，３−ジヒドロイミダゾ〔１，２−ｃ〕キナゾリン−５（６Ｈ）−オン（−チオン）、その製造方法およびその用途
EP0594877A1 (fr) * 1992-10-26 1994-05-04 National Science Council Dérivés d'imidazo(1,2-c)quinazoline comme antihypertensives et antidysuriques
JPH0832705B2 (ja) * 1992-12-14 1996-03-29 ナショナル サイエンス カウンシル 新規なメチル−２、３−ジヒドロイミダゾ〔１，２−ｃ〕キナゾリン誘導体、その製造法と用途
US5932584A (en) 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
TW591029B (en) 2002-01-04 2004-06-11 Pharmaceutical Ind Tech & Dev Antipsychotic pharmaceutical composition
AU2004255581A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US20060069124A1 (en) * 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases

Also Published As

Publication number Publication date
GB2454549A8 (en) 2009-09-02
GB2454549A (en) 2009-05-13
DE102008003054A1 (de) 2009-05-07
GB0812493D0 (en) 2008-08-13
JP4845895B2 (ja) 2011-12-28
TW200914455A (en) 2009-04-01
GB0718678D0 (en) 2007-10-31
FR2921269A1 (fr) 2009-03-27
GB2454549B (en) 2009-09-23
GB2453116A (en) 2009-04-01
US20090082373A1 (en) 2009-03-26
CN101396365A (zh) 2009-04-01
GB2453116B (en) 2010-03-17
CN101396365B (zh) 2012-04-18
US20100292257A1 (en) 2010-11-18
JP2009079029A (ja) 2009-04-16
TWI364280B (en) 2012-05-21

Similar Documents

Publication Publication Date Title
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
WO2007126935A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés diazépane
EP1691760A4 (fr) Dispositifs, systemes et procedes permettant de fixer des tissus dans certaines zones corporelles, telles que le conduit pharyngien
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
SI1613350T1 (sl) Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
UY28258A1 (es) Tratamiento terapeutico
WO2008008517A3 (fr) Diazépans pontés antagonistes du récepteur de l'oréxine
WO2008008551A3 (fr) Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine
MA33974B1 (fr) Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
WO2005012530A3 (fr) Antagonistes et agonistes de ldcam et procedes d'utilisation
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
WO2007126934A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther
WO2007087151A3 (fr) Méthode de traitement d'un dysfonctionnement cognitif
ZA201000314B (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
WO2005072308A3 (fr) Antagonistes des recepteurs du cgrp
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
WO2007141284A3 (fr) Antagonistes du peptide cgrp
BRPI0510947A (pt) tratamento de doença respiratória
NO20041024D0 (no) Anvendelse av BIBN4096 i kombinasjon med andre antimigrenelegemidler for behandling av migrene
EP1924717A4 (fr) Méthodes d'amélioration de la capacité de deshydratation de boue avec un traitement d'alpha-amylase

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18